A Phase 1 interventional study of 19 injections and sodium chloride 0.9% solution in Diabetes, Diabetes Mellitus, Type 1 and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 1 site in Germany. Open to participants aged 18 Years to 74 Years. Per ClinicalTrials.gov, last updated 2017-03-03.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 642 studies in Diabetes Mellitus by Novo Nordisk A/S — 2 open to participants now, 3 under way, 1 of them phase 3. Diabetes Mellitus · Novo Nordisk A/S.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 258th largest by enrollment of the 494 interventional ones that give a count, is one of 37 that started in 2012, is one of 206 in phase 1, and was the 443rd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,074 are open to participants now.
Browse Diabetes Mellitus studies →2 of the 642 studies in Diabetes Mellitus by Novo Nordisk A/S are open now, in 2 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in Germany
Ages 18–75
Novo Nordisk A/S · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 650 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 197 (30%) stop at 75 or younger; 88 take children under 18; 183 take healthy volunteers.
This study: 18 Years to 74 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
642 studies; the count open now beside each. This study's row is marked.
First in 1989; this study’s year is marked. 37 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 82 is close to the median of 80 across 6,024 interventional studies indexed under Diabetes Mellitus.
Median enrollment 87 across the 494 interventional studies, 1,497 across the 148 observational. Of the 636 that completed or were terminated, 163 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
1 of the studies in Diabetes Mellitus by Novo Nordisk A/S that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07535307Novo Nordisk A/SInvestigating How NNC0487-0111 Regulates Insulin of Adults With Type 2 Diabetes | 2027-11-11 |
Add it to your calendar (.ics) → With an account.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This trial is conducted in Europe. The aim of this trial is to assess and describe the pain in relation to subcutaneous (under the skin) injection of different combinations of injection speed and volume with respect to acceptance of the injection pain and backflow.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study consists of 80 treatment arms in a cross-over design with 19 treatments and 19 periods. The 80 treatment arms will represent different orders of the 19 treatments and each treatment arm will be used for one subject. A subject not completing all treatments will be replaced by another subject using the same treatment arm.
Other: 19 injections · Drug: sodium chloride 0.9% solution
Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
Solution for injection.
Injection Pain (VAS mm)
Calculated as the least square mean estimate of the difference in injection pain on a VAS (mm) between different factor levels corresponding to injection region, injection volume and injection speed (pain was assessed using an electronic VAS consisting of a 100 mm line where 0 mm corresponded to no pain and 100 mm corresponded to worst pain. After each injection, the subjects rated their pain perception at the electronic VAS by marking the 100 mm line).
Time frame: 1 minute (±30 sec) after each injection
Acceptance of Injection Pain After Injection of Different Volumes.
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
Time frame: 1 minute (±30 seconds) after each injection
Acceptance of Injection Pain After Injection at Different Speeds.
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
Time frame: 1 minute (±30 sec) after each injection
Acceptance of Injection Pain After Injection in the Thighs Versus Abdomen.
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
Time frame: 1 minute (±30 seconds) after each injection
Estimated Mean Differences in the Volume of Backflow (uL) in the Abdomen After Different Injection Volumes and Speeds as Compared to Needle Insertion
Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.
Time frame: 2 minutes (±30sec) after each injection
Estimated Mean Differences in the Volume of Backflow (uL) in the Thighs After Different Injection Volumes and Speeds as Compared to Needle Insertion
Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.
Time frame: 2 minutes (±30sec) after each injection
The trial was conducted at a single site in Germany at a single visit.
| Milestone | All Participants |
|---|---|
| Started | 82 |
| Subjects missing injections | 2 |
| Completed | 80 |
| Not completed | 2 |
Calculated as the least square mean estimate of the difference in injection pain on a VAS (mm) between different factor levels corresponding to injection region, injection volume and injection speed (pain was assessed using an electronic VAS consisting of a 100 mm line where 0 mm corresponded to no pain and 100 mm corresponded to worst pain. After each injection, the subjects rated their pain perception at the electronic VAS by marking the 100 mm line).
| mm | Thighs: Injection Region-5 s.c Injections+1 Needle Insertion | Abdomen: Injection Region-12 s.c Injections+1 Needle Insertion | Injection Volume 1600 μL | Injection Volume 1200 μL | Injection Volume 800 μL | Injection Volume 400 μL | Injection Speed at 450 μL/s | Injection Speed at 300 μL/s | Injection Speed at 150 μL/s |
|---|---|---|---|---|---|---|---|---|---|
| Needle insertion | 20.0 ± 24.2 | 12.8 ± 16.3 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 150 μL/s; Abdomen | NA ± NA | NA ± NA | 20.9 ± 24.4 | 15.7 ± 20.2 | 11.6 ± 15.7 | 14.5 ± 17.3 | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 300 μL/s; Abdomen | NA ± NA | NA ± NA | 17.2 ± 22.5 | 20.1 ± 25.3 | 13.7 ± 17.1 | 14.8 ± 18.1 | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 450 μL/s; Abdomen | NA ± NA | NA ± NA | 21.1 ± 24.8 | 14.9 ± 16.9 | 14.8 ± 18.9 | 12.4 ± 15.5 | NA ± NA | NA ± NA | NA ± NA |
| Injection volume of 400 μL; Thighs | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 20.9 ± 24.8 | NA ± NA | 22.9 ± 25.9 |
| Injection volume of 800 μL; Thighs | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 23.2 ± 24.5 | NA ± NA |
| Injection volume of 1600 μL; Thighs | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | 31.1 ± 28.5 | NA ± NA | 31.5 ± 28.0 |
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
| scores | Injection Volume of 1600 μL | Injection Volume of 1200 μL | Injection Volume of 800 μL | Injection Volume of 400 μL |
|---|---|---|---|---|
| Yes | 334 | 218 | 303 | 368 |
| No | 75 | 28 | 25 | 41 |
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
| scores | Injection Speed at 450 μL/s | Injection Speed at 300 μL/s | Injection Speed at 150 μL/s |
|---|---|---|---|
| Yes | 432 | 365 | 426 |
| No | 59 | 44 | 66 |
Acceptance of pain was rated subjectively as yes or no by the subject after each injection.
| scores | Thighs | Abdomen |
|---|---|---|
| Yes | 390 | 978 |
| No | 101 | 87 |
Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.
| mcL | Abdomen: Injection Region-12 s.c Injections+1 Needle Insertion | Injection Volume 1600 μL | Injection Volume 1200 μL | Injection Volume 800 μL | Injection Volume 400 μL | Injection Speed at 450 μL/s | Injection Speed at 300 μL/s | Injection Speed at 150 μL/s |
|---|---|---|---|---|---|---|---|---|
| Needle insertion | 0.0 ± 0.1 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 150 μL/s | NA ± NA | 2.3 ± 5.1 | 0.9 ± 1.9 | 0.5 ± 1.4 | 0.6 ± 1.8 | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 300 μL/s | NA ± NA | 1.4 ± 2.9 | 0.8 ± 1.9 | 0.5 ± 1.6 | 0.4 ± 1.3 | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 450 μL/s | NA ± NA | 0.6 ± 1.1 | 1.1 ± 4.6 | 0.5 ± 1.3 | 0.9 ± 2.7 | NA ± NA | NA ± NA | NA ± NA |
Backflow was measured after each injection by placing a filter paper over the injection site after the injection was given and until the liquid was absorbed. The size of the wet spot on the filter paper served as a measure of the backflow. The treatment effect on backflow was calculated as the least square mean estimate of the difference in backflow after injection in the abdomen at different volume and speed combinations.
| mcL | Thighs: Injection Region-5 s.c Injections+1 Needle Insertion | Injection Volume 1600 μL | Injection Volume 800 μL | Injection Volume 400 μL | Injection Speed at 450 μL/s | Injection Speed at 300 μL/s | Injection Speed at 150 μL/s |
|---|---|---|---|---|---|---|---|
| Needle insertion | 0.8 ± 5.6 | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 150 μL/s | NA ± NA | 5.6 ± 8.6 | NA ± NA | 1.0 ± 3.1 | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 300 μL/s | NA ± NA | NA ± NA | 2.3 ± 7.9 | NA ± NA | NA ± NA | NA ± NA | NA ± NA |
| Injection speed at 450 μL/s | NA ± NA | 2.5 ± 4.6 | NA ± NA | 1.6 ± 4.9 | NA ± NA | NA ± NA | NA ± NA |
Collected over From Day 0 when receiving 19 injections and up to 48 hours after last injection.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| All Participants | — | 0/82 (0%) | 0/82 (0%) |
| Age, Continuous(years) | All Participants |
|---|---|
| Mean | 54.3 ± 11.9 |
| Gender(Participants) | All Participants |
|---|---|
| Female | 32 |
| Male | 50 |
The record gives a start of Aug 2012, a primary completion of Oct 2012 and a completion of Oct 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Chloride